Category Archives: OTC

Terra Tech Corp. (TRTC: OTCQB) | Terra Tech Subsidiary, MediFarm, Secures Permits to Operate Two Additional Nevada Medical Cannabis Dispensaries

Las Vegas, Sept. 03, 2015 (GLOBE NEWSWIRE) — Terra Tech Corp  (TRTC), is pleased to give an update on the continued expansion and development of Blum ™ and MediFarm in Nevada. Today, Terra Tech’s subsidiary, MediFarm, received approvals from Unincorporated Clark County for two Land Use Applications for medical cannabis dispensaries to be located at 1130 East Desert Inn Road and 3650 South Decatur Blvd. The Company has already received a provisional operational certificate from the State of Nevada Department of Health and Human Services Division of Public and Behavioral Health on 11/3/2014. MediFarm was ranked sixth and seventh out of approximately thirty-seven County dispensary applications received by the State.

“I am thrilled at the results today in Clark County. Our team has worked extremely hard on these applications and we look forward to building out two additional retail storefronts that can provide exceptional service to the patients of Nevada,” explains Derek Peterson, CEO of Terra Tech. “We now have four dispensaries, two cultivation centers, and two production and extraction facilities to design and build, making us one of the largest operators within the State. We feel comfortable with our ability to both fund and manage the multiple construction projects and we will immediately begin working with our architects and builders to break ground as quickly as possible.”

The Company will issue additional updates on their other Nevada projects in the near future.​

 

About Terra Tech

Terra Tech Corp. (TRTC) through its wholly-owned subsidiary GrowOp Technology, specializes in controlled environment agricultural technologies. The company integrates best-of-breed hydroponic equipment with proprietary software and hardware to provide sustainable solutions for indoor agriculture enterprises and home practitioners. Our complete product line is available at specialty retailers throughout the United States, and via our website. Through its wholly-owned subsidiary Edible Garden, cultivates a premier brand of local and sustainably grown hydroponic produce, sold through major grocery stores such as Shoprite, Walmart, Krogers and others throughout New Jersey, New York, Delaware, Maryland, Connecticut, Pennsylvania and the Midwest. MediFarm LLC is focused on medical cannabis businesses throughout Nevada. IVXX LLC is a wholly owned subsidiary that produces medical cannabis extracted products for regulated medical cannabis dispensaries throughout California.

For more information about Terra Tech Corp visit: www.terratechcorp.com

For more information about IVXX visit: www.ivxx.com

Visit us on Facebook @ http://www.facebook.com/terratechcorp

Follow us on Twitter @terratechcorp

Follow us on Instagram @socal_IVXX

For more information about Edible Garden visit: http://www.ediblegarden.com

Visit Edible Garden on Facebook @ https://www.facebook.com/ediblefarms

Visit IVXX on Facebook @ https://www.facebook.com/ivxxbrand

Cautionary Language Concerning Forward-Looking Statements

Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Terra Tech Corp.’s filings with the Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to Terra Tech Corp.’s (i) product demand, market and customer acceptance of its equipment and other goods, (ii) ability to obtain financing to expand its operations, (iii) ability to attract qualified sales representatives, (iv) competition, pricing and development difficulties, (v) ability to integrate GrowOp Technology Ltd. into its operations as a reporting issuer with the Securities and Exchange Commission, and (vi) general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on Terra Tech Corp.’s website does not constitute a part of this release.

Bill Clayton 
Independence Financial Ltd. 
Toll-Free: (888) 603-2896 
Email: info@terratechcorp.com

Primary Logo

Article source: http://www.otcmarkets.com/stock/TRTC/news?id=113685

InSite Vision, Inc. (INSV: OTCQB) | InSite Vision Announces New Date for Special Stockholder Meeting

InSite Vision Announces New Date for Special Stockholder Meeting

Sep 02, 2015

OTC Disclosure News Service

InSite Vision Incorporated (OTCBB:INSV), a company developing ophthalmic
products for unmet eye care needs, today announced that the company’s
Special Meeting of Stockholders to vote on certain matters in connection
with the transaction with QLT Inc., including a proposal to adopt a
Second Amended and Restated Agreement and Plan of Merger, will now be
held at 10:00 a.m. Pacific Time on October 9, 2015, for stockholders of
record on September 8, 2015. InSite Vision had previously announced that
the Special Meeting would be held on September 30, 2015. The Special
Meeting will be held at InSite Vision’s headquarters at 965 Atlantic
Avenue, Alameda, California. InSite Vision plans to mail the definitive
proxy statement for the Special Meeting in early September 2015.

About InSite Vision

InSite is advancing new specialty ophthalmologic products for treatment
of diseases affecting the front and back of the eye. The company has two
commercial products based on its innovative DuraSite®
platform approved for the treatment of bacterial eye infections, AzaSite®
(azithromycin ophthalmic solution) 1%, marketed in the U.S. by Akorn,
Inc., and Besivance® (besifloxacin ophthalmic suspension)
0.6%, marketed by Bausch Lomb, a wholly owned subsidiary of Valeant
Pharmaceuticals International. InSite has a proprietary portfolio of
clinical-stage product candidates, and has recently filed an NDA for
BromSite™ for the treatment of inflammation and prevention of pain
associated with cataract surgery. InSite currently plans to file an NDA
with the FDA in 2017 for the commercial approval by the U.S. Food and
Drug Administration (FDA) of DexaSite™ for the treatment of blepharitis.
InSite’s AzaSite Plus™ is advancing through Phase 3 clinical studies for
the treatment of eye infections, and ISV-101 is in Phase 1/2 clinical
development for dry-eye disease and inflammation. For further
information on InSite, please visit www.insitevision.com.

No Offer or Solicitation

This communication is not intended to and does not constitute an offer
to sell or the solicitation of an offer to subscribe for or buy or an
invitation to purchase or subscribe for any securities or the
solicitation of any vote or approval in any jurisdiction pursuant to the
acquisition or otherwise, nor shall there be any sale, issuance or
transfer of securities in any jurisdiction in contravention of
applicable law.

Additional Information

In connection with the proposed merger of InSite Vision and QLT, QLT
filed with the U.S. Securities and Exchange Commission (SEC) a
Registration Statement on Form S-4 that includes a preliminary proxy
statement of InSite Vision and that also constitutes a preliminary
prospectus of QLT (the Form S-4). The Form S-4 has not yet been declared
effective by the SEC and is not complete and will be further amended.
InSite Vision plans to mail the definitive proxy statement/prospectus to
its stockholders when it becomes available. INVESTORS ARE URGED TO READ
THE DEFINITIVE PROXY STATEMENT/ PROSPECTUS AND ANY OTHER RELEVANT
DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THOSE
DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and security
holders will be able to obtain free copies of the definitive proxy
statement/prospectus (when available) and other documents filed with the
SEC by QLT or InSite through the website maintained by the SEC at http://www.sec.gov
and, in QLT’s case, also on the System for Electronic Document Analysis
Retrieval (SEDAR) website maintained by the Canadian Securities
Administrators at www.sedar.com.
Copies of the documents filed with the SEC by InSite will be available
free of charge on InSite’s website at www.InSiteVision.com
or by contacting InSite at 510-747-1220.

Participants in the Merger Solicitation

QLT, InSite Vision, their respective directors and certain of their
executive officers and employees may be considered participants in the
solicitation of proxies in connection with the proposed transaction.
Information regarding the persons who may, under the rules of the SEC,
be deemed participants in the solicitation of the QLT and InSite Vision
shareholders in connection with the proposed merger and a description of
their direct and indirect interests, by security holdings or otherwise,
will be set forth in the proxy statement/prospectus when it is filed
with the SEC. Information about the directors and executive officers of
QLT is set forth in its Annual Report on Form 10-K/A, which was filed
with the SEC on April 30, 2015. Information about the directors and
executive officers of InSite Vision is set forth in its proxy statement
for its 2015 annual meeting of shareholders, which was filed with the
SEC on February 19, 2015.

Cautionary Statements Related to Forward-Looking Statements

Statements in this document that are not strictly historical, including
statements may be “forward-looking” statements within the meaning of the
Private Securities Litigation Reform Act of 1995, and involve a number
of risks and uncertainties. There are a number of important factors that
could cause actual events to differ materially from those suggested or
indicated by such forward-looking statements and you should not place
undue reliance on any such forward-looking statements. These factors
include risks and uncertainties related to, among other things: general
economic conditions and conditions affecting the industries in which
InSite Vision operates; the commercial success of InSite Vision’s
products; each of the parties’ ability to satisfy merger agreement
conditions and consummate a merger on the anticipated timeline or at
all; QLT’s ability to successfully integrate InSite Vision’s operations
and employees with QLT’s existing business; the ability to realize
anticipated growth, synergies and cost savings; research and development
risks; the potential that the scheduled meeting will be delayed to
solicit additional votes. Additional information regarding the factors
that may cause actual results to differ materially from these
forward-looking statements is available in (i) QLT’s SEC filings,
including its Annual Report on Form 10-K (as amended) for the fiscal
year ended December 31, 2014 and Quarterly Report on Form 10-Q for the
quarterly period ended March 31, 2015 under the caption “Risk Factors”
and elsewhere in such reports; and (ii) InSite Vision’s SEC filings,
including its Annual Report on Form 10-K for the fiscal year ended
December 31, 2014 and Quarterly Report on Form 10-Q for the quarterly
period ended March 31, 2015 under the caption “Risk Factors” and
elsewhere in such reports. The forward-looking statements made herein
speak only as of the date hereof and none of QLT, InSite Vision or any
of their respective affiliates assumes any obligation to update or
revise any forward-looking statement, whether as a result of new
information, future events and developments or otherwise, except as
required by law.

AzaSite® and DuraSite® are registered trademarks
of InSite Vision Incorporated.
AzaSite Plus, BromSite™
and DexaSite™ are trademarks of InSite Vision Incorporated.
BESIVANCE®
is a registered trademark of Bausch + Lomb Incorporated.

Copyright © 2015 Businesswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/INSV/news?id=113649

Calvin B. Taylor Bankshares, Inc. (TYCB: OTCQX U.S. Premier) | New Branch Application

New Branch Application

Sep 02, 2015

OTC Disclosure News Service

Berlin, MD

This release includes additional documents. Select the link(s) below to view.

Press Release – New Branch Application.pdf

Copyright © 2015 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/TYCB/news?id=113619

Bunk Beds